Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates

Histology and Histopathology

Volumn 23, Issue 1, 2008, Pages 33-40

  Zudaire, I ^a,b   Lozano, D M ^b   Vazquez, M F ^c   Pajares, M J ^a,b   Agorreta, J ^a,b   Pio, R ^a,b   Zulueta, J J ^d   Yankelevitz, D F ^c   Henschke, C I ^e   Montuenga, Luis M ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e NONE

Author keywords

Fine needle aspiration cytology; Fluorescence in situ hybridization; Immuno cytochemistry; Lung cancer screening

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HER1 PROTEIN, HUMAN; KI 67 ANTIGEN; MYC PROTEIN; MYC PROTEIN, HUMAN; PARAFFIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PARAFFIN EMBEDDING; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 35748935247     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Aoki T., Tomoda Y., Watanabe H., Nakata H., Kasai T., Hashimoto H., Kodate M., Osaki T. and Yasumoto K. (2001). Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology 220, 803-809.
2. Asamura H., Suzuki K., Watanabe S., Matsuno Y., Maeshima A. and Tsuchiva R. (2003). A clinicopathological study of resected subcentimeter lung cancers: a favorable prognosis for ground glass opacity lessions. Ann. Thorac. Surg. 76, 1016-1022.
3. Aviram G., Schwartz D.S., Meirsdorf S., Rosen G., Greif J. and Graif M. (2005). Transthoracic needle biopsy of lung masses: a survey of techniques. Clin. Radiol. 60, 370-374.
4. Avva R., Vanhemert R.L., Barlogie B., Munshi N. and Angtuaco E.J. (2001). CT-guided biopsy of focal lesions in patients with multiple myeloma may reveal new and more aggressive cytogenetic abnormalities. Am. J. Neuroradiol. 22, 781-785.
5. Barkan G.A., Caraway N.P., Jiang F., Zaidi T.M., Fernandez R., Vaporcyin A., Morice R., Zhou X., Bekele B.N. and Katz R.L. (2005). Comparison of molecular abnormalities in bronchial brushings and tumor touch preparations. Cancer 105, 35-43.
6. Bastarrika G., Garcia-Velloso M.J., Lozano M.D., Montes U., Torre W., Spiteri N., Campo A., Seijo L., Alcaide A.B., Pueyo J., Cano D., Vivas I., Cosin O., Dominguez P., Serra P., Richter J.A., Montuenga L. and Zulueta J.J. (2005). Early lung cancer detection using spiral computed tomography and positron emission tomography. Am. J. Respir. Crit. Care Med. 171, 1378-1383.
7. Beatty B.G., Bryant R., Wang W., Ashikaga T., Gibson P.C., Leiman G. and Weaver D.L. (2004). HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis. Am. J. Clin. Pathol. 122, 246-255.
8. Bofin A.M., Lydersen S., Isaksen C. and Hagmar B.M. (2004). Interpretation of fine needle aspiration cytology of the breast: a comparison of cytological, frozen section, and final histological diagnoses. Cytopathology 15, 297-304.
9. Boyle P. and Ferlay J. (2005). Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16, 481-488.
10. Bubendorf L., Muller P., Joos L., Grilli B., Vogel S., Herzog M., Barascud A., Feichter G., Dalquen P. and Tamm M. (2005). Multitarget FISH analysis in the diagnosis of lung cancer. Am. J. Clin. Pathol. 123, 516-523.
11. Burke L., Flieder D.B., Guinee D.G., Brambilla E., Freedman A.N., Bennett W.P., Jones R.T., Borkowski A., Caporaso N.A., Fleming M., Trastek V., Pairolero P., Tazelaar H., Midthun D., Jett J.R., Liotta L.A., Travis W.D. and Harris C.C. (2005). Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin. Cancer Res. 11, 232-241.
12. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., Haney J., Witta S., Danenberg K., Domenichini I., Ludovini V., Magrini E., Gregorc V., Doglioni C., Sidoni A., Tonato M., Franklin W.A., Crino L., Bunn P.A. Varella-Garcia M. (2005). Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97, 643-655.
13. Chandan V.S., Zimmerman K., Baker P., Scalzetti E. and Khurana K.K. (2004). Usefulness of core roll preparations in immediate assessment of neoplastic lung lesions: comparison to conventional CT scan-guided lung fine-needle aspiration cytology. Chest 126, 739-743.
14. Chhajed P.N., Bernasconi M., Gambazzi F., Bubendorf L., Rasch H., Kneifel S. and Tamm M. (2005). Combining bronchoscopy and positron emission tomography for the diagnosis of the small pulmonary nodule < or = 3 cm. Chest 128, 3558-3564.
15. Halling K.C., Rickman O.B., Kipp B.R., Harwood A.R., Doerr C.H. and Jett J.R. (2006). A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. Chest 130, 694-701.
16. Henschke C.I., Shaham D., Yankelevitz D.F., Kramer A., Kostis W.J., Reeves A.P., Vazquez M., Koizumi J. and Miettinen O.S. (2006). CT screening for lung cancer Significance of diagnoses in its baseline cycle. Clin. Imaging 30, 11-15.
17. Herbst R.S., Fukuoka M. and Baselga J. (2004). Gefitinib-a novel targeted approach to treating cancer. Nat. Rev. Cancer 4, 956-965.
18. Heselmeyer-Haddad K., Chaudhri N., Stoltzfus P., Cheng J.C., Wilber K., Morrison L., Auer G. and Ried T. (2002). Detection of chromosomal aneuploidies and gene copy number changes in fine needle aspirates is a specific, sensitive, and objective genetic test for the diagnosis of breast cancer. Cancer Res. 62, 2365-2369.
19. Hirsch F.R., Varella-Garcia M., McCoy J., West H., Xavier A.C., Gumerlock P., Bunn P.A., Jr., Franklin W.A., Crowley J. and Gandara D.R. (2005). Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J. Clin. Oncol. 23, 6838-6845.
20. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C. and Thun M.J. (2006). Cancer statistics, 2006. CA. Cancer J. Clin. 56, 106-130.
21. Kettunen E., Salmenkivi K., Vuopala K., Toljamo T., Kuosma E., Norppa H., Knuutila S., Kaleva S., Huuskonen M.S. and Anttila S. (2006). Copy number gains on 5p15, 6p11-q11, 7p12, and 8q24 are rare in sputum cells of individuals at high risk of lung cancer. Lung Cancer 54, 169-176.
22. Konofaos P., Tomos P. K. M., Karakatsani A., Pavlopoulos D., Lachanas E., Flessas M., Kostakis A. and Karakitsos P. (2006). The role of ThinPrep cytology in the investigation of lung tumors. Surg. Oncol. 15, 173-178.
23. Li F., Sone S., Abe H., Macmahon H. and Doi K. (2004). Malignant versus benign nodules at CT screening for lung cancer: comparison of thin-section CT findings. Radiology 233, 793-798.
24. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., Hatooka S., Shinoda M., Takahashi T. and Yatabe Y. (2005). Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23, 2513-2520.
25. Mukunyadzi P., Bardales R.H., Wilson C.S., Sawyer J.R. and Stanley M.W. (2001). Soft tissue masses in patients with multiple myeloma: a fine-needle aspiration study of 30 cases with flow cytometry and clinical correlation. Cancer 93, 257-262.
26. Mulshine J.L. (2003). Screening for lung cancer: in pursuit of pre- metastatic disease. Nat. Rev. Cancer 3, 65-73.
27. Mulshine J.L. and Sullivan D.C. (2005). Clinical practice. Lung cancer screening. N. Engl. J. Med. 352, 2714-2720.
28. Mundle S.D. and Sokolova I. (2004). Clinical implications of advanced molecular cytogenetics in cancer. Expert Rev. Mol. Diagn. 4, 71-81.
29. Nakamura H., Aute I., Kawasaki N., Taguchi M., Ohira T. and Kato H. (2005). Quantitative detection of lung cancer cells by fluorescence in situ hybridization: comparison with conventional cytology. Chest 128, 906-911.
30. Ohta Y., Shimizu Y., Kobayashi T., Matsui O., Minato H., Matsumoto I. and Watanabe G. (2006). Pathologic and biological assessment of lung tumors showing ground-glass opacity. Ann. Thorac. Surg. 81, 1194-1197.
31. Oliveira A.M. and French C.A. (2005). Applications of fluorescence in situ hybridization in cytopathology. Acta Cytol. 49, 587-594.
32. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E. and Meyerson M. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304, 1497-1500.
33. Pajares M.J., Zudaire I., Lozano M.D., Agorreta J., Bastarrika G., Torre W., Remírez A., Pío R., Zulueta J.J. and Montuenga L. (2006). Molecular profiling of CT screen detected lung nodules shows multiple malignant features. Cancer Epidemiol. Biomarkers Prev. 15, 373-380.
34. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S. and Gelber R.D. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672.
35. Romeo M.S., Sokolova I.A., Morrison L.E., Zeng C., Baron A.E., Hirsch F.R., Miller Y.E., Franklin W.A. and Varella-Garcia M. (2003). Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization. J. Mol. Diagn. 5, 103-112.
36. Safley A.M., Buckley P.J., Creager A.J., Dash R.C., Dodd L.G., Goodman B.K., Jones C.K., Lagoo A.S., Stenzel T.T., Wang W., Xie. and Gong J.Z. (2004). The value of fluorescence in situ hybridization and polymerase chain reaction in the diagnosis of B- cell non-Hodgkin lymphoma by fine-needle aspiration. Arch. Pathol. Lab. Med. 128, 1395-1403.
37. Singhal S., Vachani A., Antin-Ozerkis D., Kaiser L.R. and Albelda S.M. (2005). Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin. Cancer Res. 11, 3974-3986.
38. Sokolova I.A., Bubendorf L., O'Hare A., Legator M.S., Jacobson K.K., Grilli B.S.B., Dalquen P., Halling K.C., Tamm M., Seelig S.A. and Morrison L.E. (2002). A fluorescence in situ hybridization-based assay for improved detection of lung cancer cells in bronchial washing specimens. Cancer 96, 306-315.
39. Steels E., Paesmans M., Berghmans T., Branle F., Lemaitre F., Mascaux C., Meert A.P., Vallot F., Lafitte J.J. and Sculier J.P. (2001). Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur. Respir. J. 18, 705-719.
40. The International Early Lung Cancer Action Program Investigators. (2006). Survival of patients with stage I lung cancer detected on CT screening. N. Engl. J. Med. 355, 1763-1771.
41. Takashima S., Maruyama Y., Hasegawa M., Yamanda T., Honda T., Kadoya M. and Sone S. (2002). Prognostic significance of high- resolution CT findings in small peripheral adenocarcinoma of the lung: A retrospective study on 64 patients. Lung Cancer 36, 289-295.
42. Tateishi U., Uno H., Yonemori K., Satake M., Takeuchi M. and Arai Y. (2005). Prediction of lung adenocarcinoma without vessel invasion: A CT scan volumetric analysis. Chest 128, 3276-3283.
43. Travis W.D., Garg K., Franklin W.A., Wistuba I.I., Sabloff B., Noguchi M., Kakinuma R., Zakowski M., Ginsberg M., Padera R., Jacobson F., Johnson B.E., Hirsch F., Brambilla E., Flieder D.B., Geisinger K.R., Thunnisen F., Kerr K., Yankelevitz D., Franks T.J., Galvin J.R., Henderson D.W., Nicholson A.G., Hasleton P.S., Roggli V., Tsao M.S., Cappuzzo F. and Vazquez M. (2005). Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J. Clin. Oncol. 23, 3279-3287.
44. Varella-Garcia M. (2003). Molecular cytogenetics in solid tumors: laboratorial tool for diagnosis, prognosis, and therapy. Oncologist 8, 45-58.
45. Varella-Garcia M., Kittelson J., Schulte A.P., Vu K.O., Wolf H.J., Zeng C., Hirsch F.R., Byers T., Kennedy T., Miller Y.E., Keith R.L. and Franklin W.A. (2004) Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer. Cancer Detect. Prev. 28, 244-251
46. Woenckhaus M., Grepmeier U., Wild P.J., Merk J., Pfeifer M., Woenckhaus U., Stoelcker B., Blaszyk H., Hofstaedter F., Dietmaier W. and Hartmann A. (2005). Multitarget FISH and LOH analyses at chromosome 3p in non-small cell lung cancer and adjacent bronchial epithelium. Am. J. Clin. Pathol. 123,752-761.